Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity

European Journal of Pharmacology

Volumn 583, Issue 1, 2008, Pages 148-155

  Yang, Yu Min ^a   Chen, Jun Zhu ^a   Wang, Xing Xiang ^a   Wang, Shi Jun ^a   Hu, Hu ^b   Wang, Hong Qiang ^b  

^a First Affiliated Hospital   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Phospholipase C ; Phospholipase C inhibitor; Platelet; Resveratrol; Thromboxane A2 receptor agonist

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; PADGEM PROTEIN; PHOSPHOLIPASE C; PHOSPHOLIPASE C BETA3; PHOSPHOLIPASE C INHIBITOR; RESVERATROL; THROMBOXANE A2 RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPOIESIS; THROMBOEMBOLISM;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADULT; BLOOD PLATELETS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; ENZYME INHIBITORS; ESTRENES; FLOW CYTOMETRY; HUMANS; ISOENZYMES; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PYRROLIDINONES; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SIGNAL TRANSDUCTION; STILBENES; TYPE C PHOSPHOLIPASES;

EID: 39649090942     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.009     Document Type: Article

References (58)

1. Allison G.L., Lowe G.M., and Rahman K. Aged garlic extract may inhibit aggregation in human platelets by suppressing calcium mobilization. J. Nutr. 136 (2006) 789-792
2. Ault K.A., Cannon C.P., Mitchell J., McCahan J., Tracy R.P., Novotny W.F., Reimann J.D., and Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial: thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. 33 (1999) 634-639
3. Awtry E.H., and Loscalzo J. Aspirin. Circulation 101 (2000) 1206-1218
4. Berridge M.J., and Irvine R.F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 312 (1984) 315-321
5. Bleasdale J.E., Bundy G.L., Bunting S., Fitzpatrick F.A., Huff R.M., Sun F.F., and Pike J.E. Inhibition of phospholipase C dependent processes by U-73122. Adv. Prostaglandin Thromboxane Leukotriene Res. 19 (1989) 590-593
6. Bleasdale J.E., Thakur N.R., Gremban R.S., Bundy G.L., Fitzpatrick F.A., Smith R.J., and Bunting S. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther. 255 (1990) 756-768
7. Born G.V.R. The aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194 (1962) 927-929
8. Burger P.C., and Wagner D.D. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101 (2003) 2661-2666
9. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N., and FitzGerald G.A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 (2001) 1809-1817
10. Chronos N.A., Wilson D.J., Janes S.L., Hutton R.A., Buller N.P., and Goodall A.H. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. Clin. Sci. (Lond) 87 (1994) 575-580
11. Crabos M., Fabbro D., Stabel S., and Erne P. Effect of tumor-promoting phorbol ester, thrombin and vasopressin on translocation of three distinct protein kinase C isoforms in human platelets and regulation by calcium. Biochem. J. 288 (1992) 891-896
12. Dogné J.M., de Leval X., Neven P., Rolin S., Wauters J., David J.L., Delarge J., and Massereel B. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot. Essent. Fat. Acids 62 (2000) 311-317
13. Dogné J.M., Wouters J., Rolin S., Michaux C., Pochet L., Durant F., Delarge J., and Masereel B. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J. Pharm. Pharmacol. 53 (2001) 669-680
14. El-Mowafy A.M. Resveratrol activates membrane-bound guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem. Biophys. Res. Commun. 291 (2002) 1218-1224
15. Farndale R.W., Sixma J.J., Barnes M.J., and De Groot P.G. The role of collagen in thrombosis and hemostasis. J. Thromb. Haemost. 2 (2004) 561-573
16. FitzGerald G.A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am. J. Cardiol. 68 (1991) 11-15
17. Fukami K. Structure, regulation, and function of phospholipase C isozymes. J. Biochem. (Tokyo) 131 (2002) 293-299
18. Furie B., Furie B.C., and Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granular secretion, signaling and cell adhesion. Thromb. Haemost. 86 (2001) 214-221
19. Furie B., and Furie B.C. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends. Mol. Med. 10 (2004) 171-178
20. Grønbaek M. Alcohol, type of alcohol, and all-cause and coronary heart disease mortality. Ann. N. Y. Acad. Sci. 957 (2002) 16-20
21. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., and Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol 88 (2001) 230-235
22. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41 (2003) 961-965
23. Ha K.S., and Exton J.H. Differential translocation of protein kinase C isozymes by thrombin and platelet-derived growth factor. A possible function for phosphatidylcholine-derived diacylglycerol. J. Biol. Chem. 268 (1993) 10534-10539
24. Hamburger S.A., and Mcever R.P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 75 3 (1990) 550-555
25. Hou C., Kirchner T., Singer M., Matheis M., Argentieri D., and Cavender D. In vivo activity of a PLC inhibitor, U73122, in acute and chronic inflammatory reactions. J. Pharmacol. Exp. Ther. 309 (2004) 697-704
26. Hourani S.M., and Cusack N.J. Pharmacological receptors on blood platelets. Pharmacol. Rev. 43 (1991) 243-298
27. Hug H., and Sarre T.F. Protein kinase C isoenzymes: divergence in signal transduction?. Biochem. J. 291 (1993) 329-343
28. Irvine R.F. Nuclear lipid signaling. Nat. Rev. Mol. Cell. Biol. 4 (2003) 349-360
29. Jackson S.P., Nesbitt W.S., and Kulkarni S. Signaling events underlying thrombus formation. Thromb. Haemost. 1 (2003) 1602-1612
30. Jhon D.Y., Lee H.H., Park D., Lee C.W., Lee K.H., Yoo O.J., and Rhee S.G. Cloning, sequencing, purification, and Gq-dependent activation of phospholipase C-beta 3. J. Biol. Chem. 268 (1993) 6654-6661
31. Jneid H., Bhatt D.L., Corti R., Badimon J.J., Fuster V., and Francis G.S. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch. Intern. Med. 163 (2003) 1145-1153
32. Lee C.W., Lee K.H., Lee S.B., Park D., and Rhee S.G. Regulation of phospholipase C-beta 4 by ribonucleotides and the alpha subunit of Gq. J. Biol. Chem. 269 (1994) 25335-25338
33. Leger A.S., Cochrane A.L., and Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet 366 (2005) 1911-1912
34. Lian L., Wang Y., Draznin J., Eslin D., Bennett J.S., Poncz M., Wu D., and Abrams C.S. The relative role of PLC beta and PI3K gamma in platelet activation. Blood 106 (2005) 110-117
35. Lockhart L.K., and McNicol A. The phospholipase C inhibitor U73122 inhibits phorbol ester-induced platelet activation. J. Pharmacol. Exp. Ther. 289 (1999) 721-728
36. Marquardt L., Ruf A., Mansmann U., Winter R., Schuler M., and Buggle F. Course of platelet activation markers after ischemic stroke. Stroke 33 (2002) 2570-2574
37. Martin T.F. PI(4,5)P(2) regulation of surface membrane traffic. Curr. Opin. Cell. Biol. 13 (2001) 493-499
38. McEver R.P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb. Haemost. 86 (2001) 746-756
39. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334 (1988) 661-665
40. Opie L.H., and Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur. Heart. J. 28 (2007) 1683-1693
41. Palabrica T., Lobb R., Furie B.C., Aronovitz M., Benjamin C., Hsu Y.M., Sajer S.A., and Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359 (1992) 848-851
42. Park D., Jhon D.Y., Lee C.W., Ryu S.H., and Rhee S.G. Removal of the carboxyl-terminal region of phospholipase C-beta 1 by calpain abolishes activation by G alpha q. J. Biol. Chem. 268 (1993) 3710-3714
43. Rahman K. Historical perspective on garlic and cardiovascular disease. J. Nutr. 131 (2001) 977-979
44. Rebecchi M.J., and Pentyala S.N. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol. Rev. 80 (2000) 1291-1335
45. Renaud S., and de Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary artery disease. Lancet 339 (1992) 1523-1526
46. Rhee S.G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 70 (2001) 281-312
47. Samuelsson B., Goldyne M., Granstrom E., Hamberg M., Hammarstrom S., and Malmsten C. Prostaglandins and thromboxanes. Annu. Rev. Biochem. 47 (1978) 997-1029
48. Shah B.H., and Saeed S.A. Phosphatidylinositol 3-kinase inhibitor, wortmannin, inhibits 5-hydroxytryptamine-mediated potentiation of platelet aggregation induced by epinephrine. Res. Commun. Mol. Pathol. Pharmacol. 89 (1995) 157-164
49. Shen M.Y., Hsiao G., Liu C.L., Fong T.H., Lin K.H., Chou D.S., and Sheu J.R. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol. 139 (2007) 475-485
50. Shen R.F., and Tai H.H. Thromboxanes: synthase and receptors. J. Biomed. Sci. 5 (1998) 153-172
51. Smith R.J., Sam L.M., Justen J.M., Bundy G.L., Bala G.A., and Bleasdale J.E. Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J. Pharmacol. Exp. Ther. 253 (1990) 688-697
52. Stenberg P.E., McEver R.P., Shuman M.A., Jacques Y.V., and Bainton D.F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J. Cell. Biol. 101 (1985) 880-886
53. Stef G., Csiszar A., Lerea K., Ungvari Z., and Veress G. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J. Cardiovasc. Pharmacol. 48 (2006) 1-5
54. Tunstall-Pedoe H., Kuulasmaa K., Mahonen M., Tolonen H., Ruokokoski E., and Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations: monitoring trends and determinants in cardiovascular disease. Lancet 353 (1999) 1547-1557
55. Vogel R.A. Alcohol, heart disease, and mortality: a review. Rev. Cardiovasc. Med. 3 (2002) 7-13
56. Wagner D.D., and Burger P.C. Platelets in inflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2131-2137
57. Wu D., Katz A., Lee C.H., and Simon M.I. Activation of phospholipase C by alpha 1-adrenergic receptors is mediated by the alpha subunits of Gq family. J. Biol. Chem. 267 (1992) 25798-25802
58. Yip H.K., Wu C.J., Hang C.L., Chang H.W., Hung W.C., and Yeh K.H. Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effect of clopidogrel loading dose in inhibiting platelet activation. Circ. J. 69 (2005) 1208-121